Betahistine dihydrochloride

SKU: orb1310797

Description

Betahistine dihydrochloride is a histamine H1 receptor agonist and vasodilatory agent. It is widely used in research models for studying vestibular function, Meniere's disease, and vascular responses in both in vitro and in vivo experimental systems.

Research Area

Immunology & Inflammation, Neuroscience, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 5579-84-0
• MW: 209.12
• Purity: 99.88% (May vary between batches)
• Formula: C₈H₁₄Cl₂N₂
• SMILES: Cl.Cl.CNCCC1=NC=CC=C1
• Target: Histamine Receptor
• Solubility: Ethanol:1 mg/mL (4.78 mM);H2O:35 mg/mL (167.37 mM);DMSO:50 mg/mL (239.1 mM)

Bioactivity

• Target IC50:
  H3 receptor:1.9 μM
• In Vivo:
  In CHO(H3R) cells treated with 3 μM of, Betahistine progressively increased cAMP formation, peaking at 10 nM. Furthermore, in CHO(H3R) cells, Betahistine progressively reduced A23187-induced [3H]arachidonic acid release (EC50=0.1 nM), with the greatest effect observed at 30 nM.
• In Vitro:
  In mice, Betahistine (ED50=2 mg/kg) elevates t-MeHA levels in a dose-dependent manner. In patients with Ménière's disease, Betahistine (16 mg, twice daily for 3 months) significantly alleviates vertigo. Additionally, Betahistine (50 mg/kg) induces an upregulation of histidine decarboxylase mRNA in the nodose ganglion of the cat brain.

Storage & Handling

• Storage: keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

PT 9, PT9, PT-9, Rheumatoid, schizophrenia, inhibit, H3 receptor, episode, Ménière, Inhibitor, Histamine Receptor, HistamineReceptor, arthritis, antipsychotic, disease, Betahistine, Betahistine 2HCl, Betahistine Dihydrochloride, Betahistine dihydrochloride, CIA

Compound Identifiers

PubChem CID

68643